
Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway
Keywords: PPAR-γ; Pioglitazone; MAPK; CDKI; MCF7CDKI, Cyclin dependent kinase inhibitor; CMC, Carboxymethyl cellulose; PPAR, Peroxisome proliferator-activated receptor; PPRE, PPAR responsive element; Pio, Pioglitazone; PD, 2-(2-Chloro-4-iodo-phenylamino)-N-cyclopro